Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Burkitt’s lymphoma is a distinct subtype of non-Hodgkin’s lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addressed promptly. Optimizing the use of Food and Drug Administration-approved medications, such as combining known safe drugs, can lead to time and cost savings. This method holds promise in accelerating the progress of novel treatments, ultimately facilitating swifter access for patients. This study explores the potential of a dual-targeted therapeutic strategy, combining the bruton tyrosine kinase-targeting drug Ibrutinib and the epidermal growth factor receptor/human epidermal growth factor receptor-2-targeting drug Lapatinib. Ramos and Daudi cell lines, well-established models of Burkitt’s lymphoma, were used to examine the impact of this combination therapy. The combination of Ibrutinib and Lapatinib inhibited cell proliferation more than using each drug individually. A combination treatment induced apoptosis and caused cell cycle arrest at the S and G2/M phases. This approach is multifaceted in its benefits. It enhances the efficiency of the drug development timeline and maximizes the utility of currently available resources, ensuring a more streamlined and resource-effective research process.
Abstract
Burkitt’s lymphoma is a distinct subtype of non-Hodgkin’s lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addressed promptly. Optimizing the use of Food and Drug Administration-approved medications, such as combining known safe drugs, can lead to time and cost savings. This method holds promise in accelerating the progress of novel treatments, ultimately facilitating swifter access for patients. This study explores the potential of a dual-targeted therapeutic strategy, combining the bruton tyrosine kinase-targeting drug Ibrutinib and the epidermal growth factor receptor/human epidermal growth factor receptor-2-targeting drug Lapatinib. Ramos and Daudi cell lines, well-established models of Burkitt’s lymphoma, were used to examine the impact of this combination therapy. The combination of Ibrutinib and Lapatinib inhibited cell proliferation more than using each drug individually. A combination treatment induced apoptosis and caused cell cycle arrest at the S and G2/M phases. This approach is multifaceted in its benefits. It enhances the efficiency of the drug development timeline and maximizes the utility of currently available resources, ensuring a more streamlined and resource-effective research process.
참고문헌 (20)
- Molyneux EM, "Burkitt’s lymphoma", Lancet, 379, pp.1234~1244 (2012)[DOI]
- López C, "Burkitt lymphoma", Nat Rev Dis Primers, 8, pp.78~ (2022)[DOI]
- Salles G, "Rituximab in B-cell hematologic malignancies : a review of 20years of clinical experience", Adv Ther, 34, pp.2232~2273 (2017)[DOI]
- Xue C, "Ibrutinib in B-cell lymphoma : single fighter might be enough?", Cancer Cell Int, 20, pp.467~ (2020)[DOI]
- Kim E, "Ibrutinib inhibits pre-BCR+B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK", Blood, 129, pp.1155~1165 (2017)[DOI]
- Johnston SR, "Lapatinib : a novel EGFR", HER2 tyrosine kinase inhibitor for cancer, 2006, pp.42, 441~453
- Opdam FL, "Lapatinib for advanced or metastatic breast cancer", Oncologist, 17, pp.536~542 (2012)[DOI]
- Chipuk JE, "Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis", Science, 303, pp.1010~1014 (2004)[DOI]
- Basu A, "The relationship between BcI2, Bax and p53 : consequences for cell cycle progression and cell death", Mol Hum Reprod, 4, pp.1099~1109 (1998)[DOI]
- Herman SE, "Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL", Blood, 123, pp.3286~3295 (2014)[DOI]
- Jeong Y, "Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma : a comprehensive study on the combined effects of MS1943 and Ibrutinib", Front Oncol, 13, pp.1252658~ (2023)[DOI]
- Bilancia D, "Lapatinib in breast cancer", Ann Oncol, (18 Suppl 6), pp.vi26~vi30 (2007)[DOI]
- Kim SB, "Dual targeting of EZH2 degradation and EGFR", HER2 inhibition for enhanced efficacy against Burkitt’s lymphoma, 2023, pp.15, 4472~
- Los M, "Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling", Mol Biol Cell, 13, pp.978~988 (2002)[DOI]
- Taylor WR, "Regulation of the G2", M transition by p53, 2001, pp.20, 1803~1815
- Srivastava N, "Caspase-3 activators as anticancer agents", Curr Protein Pept Sci, 24, pp.783~804 (2023)[DOI]
- Cui Q, "P53-mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells", Acta Pharmacol Sin, 28, pp.1057~1066 (2007)[DOI]
- Nair R, "c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer", Oncogene, 33, pp.3992~4002 (2014)[DOI]
- Park C, "Induction of G2", M cell cycle arrest and apoptosis by Genistein in human bladder cancer T24 cells through inhibition of the ROSdependent PI3k, Antioxidants(Basel), pp.2019, 8[DOI]
- Xia W, "Tumor selective G2", M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine, 2000, pp.97, 7494~7499